Anti-annexin A2 antibodies in COVID-19 patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study examines the presence of anti-annexin A2 antibodies in adults hospitalized with COVID-19 at CHU Amiens. It aims to explore whether these autoantibodies are linked to immune or autoimmune responses during SARS-CoV-2 infection. The study does not assign any treatment or intervention and focuses on characterizing antibody prevalence and potential clinical associations. Eligible participants are adults 18 and older hospitalized with COVID-19, excluding those with certain autoimmune diseases, chronic viral infections, immunosuppressive therapy, solid tumors, or hematologic malignancies. Results from this study could inform understanding of autoimmune mechanisms in COVID-19 and guide future research on biomarkers and patient risk stratification.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 18 years and older
* All patients hospitalized in Amiens University Hospital with COVID-19 infection

Exclusion Criteria:

* Autoimmune diseases
* Chronic viral infection by hepatitis B virus, hepatitis C virus or human immunodeficiency virus (HIV)
* Immunosuppressive treatment
* Solid tumors
* Hematological malignancies

Where it's running

• CHU Amiens
  Amiens, France Recruiting

Study contacts

• Study coordinator: Valéry Salle, MD
• Email: salle.valery@chu-amiens.fr
• Phone: 03 22 66 82 30

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) in Adults

  This study tests and compares the immune responses and tolerability of the latest COVID-19 vaccines from Novavax and Pfizer/BioNTech in adults at risk for severe COVID-19.

  Recruiting Phase 4 Henry M. Jackson Foundation for the Advancement of Military Medicine · Bethesda, Maryland · NCT07287137

• Omicron-based COVID-19 vaccine with Matrix-M given as a single dose in older adults and high-risk individuals

  A single-dose Omicron-subvariant vaccine with Matrix-M is tested to see if it is safe and can induce an immune response in adults 65+ and in younger adults with conditions that raise the risk of severe COVID-19, who were previously vaccinated.

  Recruiting at 20 sites Phase 4 Sanofi · Fair Oaks, California and 19 other locations · NCT07861542

• Secutrelvir for nonhospitalized COVID-19 in teens and adults

  This study tests whether secutrelvir can help nonhospitalized people with COVID-19 see faster symptom relief compared with a placebo.

  Recruiting Phase 3 Shionogi Inc. · Multiple Locations · NCT07746544

• Virological Monitoring of Seasonal Respiratory Infections in France

  This project tests how often common respiratory viruses show up in patients seen by primary care doctors in metropolitan France during the fall and winter.

  Recruiting Institut National de la Santé Et de la Recherche Médicale, France · Paris · NCT07599449

• COVID-19 Registry at San Matteo (SMACORE) - patient-matching observational registry

  This registry tests how COVID-19 patients are being treated and progress across San Matteo in Pavia to understand patterns and outcomes.

  Recruiting Fondazione IRCCS Policlinico San Matteo di Pavia · Pavia · NCT07597876

• MDX2301 in healthy adults and adults at higher risk for severe COVID-19

  This study will try single and repeat doses of MDX2301 given by IV, IM, or SC to see if they are safe and trigger neutralizing activity in healthy adults and adults at higher risk for severe COVID-19.

  Recruiting at 2 sites Phase 1 ModeX Therapeutics, An OPKO Health Company · Las Vegas, Nevada and 1 other locations · NCT07445971

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.